Table 1 Study characteristics

First author (year)

Country

Fluid (dose)

Co-interventions

Co-intervention fluid volume Mean (SD)^a (L)

Fluid (dose)

Co-interventions

Co-intervention fluid volume Mean (SD)^a (L)

Bulger et al. (2011) [21]

USA Canada

7.5% HS (250 ml)

Fluid as per local protocol

1.31 (1.07)^b

0.9% NS (250 ml)

Fluid as per local protocol

1.16 (0.81)^b

Jousi et al. (2010) [22]

Finland

7.5% HS (300 ml)

Ringer’s acetate and plasmafucin or hydroxyethylstarch 6%

0.8 (0.3–1.3)^c

Ringer’s acetate and Plasmafucin or hydroxyethylstarch 6%^e

NA

0.4 (0.2–0.5)^d

Cooper et al. (2004) [23]

Australia

7.5% HS (250 ml)

LR or Haemacell (colloid)

Total fluid: 1.3 (0.8–2.3)^d Colloid: 0.5 (0.0–0.6)^d

LR (250 ml)

LR or Haemacell (colloid)

Total Fluid: 1.3 (0.8–2.3)^d Colloid: 0.3 (0.0–0.5)^d

Vassar et al. (1993a) [24]

USA

7.5% HS (250 ml)

“conventional isotonic fluids”

Pre-intervention: 1.2 (1.1) Post-intervention: 1.0 (0.8)

LR (250 ml)

“conventional isotonic fluids”

Pre-control: 1.3 (1.2) Post-control: 1.0 (0.9)

Vassar et al. (1993b) [25]

USA

7.5% HS (250 ml)

“conventional isotonic fluids”

Pre-intervention: 0.3 (0.4) Post-intervention: 1.2 (0.8)

0.9% NS (250 ml)

“conventional isotonic fluids”

Pre-control: 0.3 (0.6) Post-control: 1.1 (0.8)